Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.
The New York Times reports on international efforts to oversee and regulate gene-editing work.
New Scientist reports on new study of gene drives in mice that found that they might not work as hoped.
In Nature this week: study of gene drive feasibility in lab mice, circulating tumor DNA from cerebrospinal fluid to track glioma progression, and more.
The qPCR assay measures methylation of six genes and could help doctors identify aggressive vs indolent prostate cancer more accurately than PSA.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
The project has signed up about 170,000 participants so far, of whom 100,000 are fully enrolled, and plans to enhance recruitment through pop-up clinics.
At the Precision Medicine World Conference, researchers from Sanford Health, Providence Health, and Israel's Maccabi discussed their genomics programs.
The FDA said it is the first test authorized to test for M. genitalium, a slow-growing bacteria that is difficult to detect with traditional laboratory methods.
Three long-read assemblies — two from PacBio data alone and one from Oxford Nanopore and Illumina data — had considerably more indel errors in genes than short-read assemblies.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.